VANCOUVER, Canada I July 17, 2018 I Advanced Proteome Therapeutics Corporation (“APC” or the “Company”) (TSXV:APC) (FSE:0E8), is pleased to announce the collaboration of APC with Noria Pharmaceuticals Inc. in the rapidly growing field of antibody radioisotope conjugates.
APC will test its proprietary, site-selective, linker technology with Noria’s proprietary MacroPA radioisotope chelation technology in combination with antibodies known to preferentially target cancer cells. The scope of the current work will include investigations utilizing cell lines and animal studies.
Dr. Allen Krantz, CSO and Founder of APC commented, “APC’s linker technology represents a significant advance toward enabling the creation of a new generation of ADCs with superior potency and less toxicity. Our goal will be to extend the scope of our technology and make an important contribution to the emerging field of radioimmunotherapy that the company can capitalize on commercially.”
Bill Dickie, President and CEO of APC added, “Radioimmunotherapy using alpha and beta emitting isotopes is an area of rapid development and investment. Major Pharma companies have made multi-billion-dollar acquisitions in the field and a number of emerging companies have benefitted from significant venture funding. Noria’s principals are radiopharmaceutical industry veterans who are demonstrating that they have best-in-class radioisotope chelation technology. APC is very pleased to be working with them.”
Dr. Allan Green, President and CEO of Noria commented, “We are excited to extend our network of collaborators to include APC and look forward to working with them to create superior antibody-based therapies.”
ABOUT THE COMPANIES:
Advanced Proteome Therapeutics Corporation is developing a proprietary technology to directly target cancerous tumors and avoid destroying normal cells. This type of agent is capable of greater potency, higher specificity and lower toxicity than other therapies that can also attack healthy cells. The Company is working to streamline the process by which these agents are prepared, which to date, has been extremely cumbersome, limiting their potential.
Noria Therapeutics Inc. is developing diagnostic and therapeutic radiopharmaceutical agents based on its proprietary Trillium™ structural chemistry and its proprietary MacroPA™ radioisotope chelate technology which provide agents with controllable pharmacokinetics with improved tumor targeting properties.
SOURCE: Advanced Proteome Therapeutics
Post Views: 207
VANCOUVER, Canada I July 17, 2018 I Advanced Proteome Therapeutics Corporation (“APC” or the “Company”) (TSXV:APC) (FSE:0E8), is pleased to announce the collaboration of APC with Noria Pharmaceuticals Inc. in the rapidly growing field of antibody radioisotope conjugates.
APC will test its proprietary, site-selective, linker technology with Noria’s proprietary MacroPA radioisotope chelation technology in combination with antibodies known to preferentially target cancer cells. The scope of the current work will include investigations utilizing cell lines and animal studies.
Dr. Allen Krantz, CSO and Founder of APC commented, “APC’s linker technology represents a significant advance toward enabling the creation of a new generation of ADCs with superior potency and less toxicity. Our goal will be to extend the scope of our technology and make an important contribution to the emerging field of radioimmunotherapy that the company can capitalize on commercially.”
Bill Dickie, President and CEO of APC added, “Radioimmunotherapy using alpha and beta emitting isotopes is an area of rapid development and investment. Major Pharma companies have made multi-billion-dollar acquisitions in the field and a number of emerging companies have benefitted from significant venture funding. Noria’s principals are radiopharmaceutical industry veterans who are demonstrating that they have best-in-class radioisotope chelation technology. APC is very pleased to be working with them.”
Dr. Allan Green, President and CEO of Noria commented, “We are excited to extend our network of collaborators to include APC and look forward to working with them to create superior antibody-based therapies.”
ABOUT THE COMPANIES:
Advanced Proteome Therapeutics Corporation is developing a proprietary technology to directly target cancerous tumors and avoid destroying normal cells. This type of agent is capable of greater potency, higher specificity and lower toxicity than other therapies that can also attack healthy cells. The Company is working to streamline the process by which these agents are prepared, which to date, has been extremely cumbersome, limiting their potential.
Noria Therapeutics Inc. is developing diagnostic and therapeutic radiopharmaceutical agents based on its proprietary Trillium™ structural chemistry and its proprietary MacroPA™ radioisotope chelate technology which provide agents with controllable pharmacokinetics with improved tumor targeting properties.
SOURCE: Advanced Proteome Therapeutics
Post Views: 207
